ADNA

AdnaGen is a biotechnology company that pioneered the field of liquid biopsy through the detection and molecular analysis of circulating tumor cells (CTCs). The company's proprietary AdnaTest platform utilizes a unique combination of immunomagnetic cell enrichment and highly sensitive RT-PCR to identify tumor-specific biomarkers from simple blood samples. This technology enables the characterization of cancer at the molecular level, facilitating treatment monitoring and the identification of therapeutic targets in a minimally invasive manner. AdnaGen was acquired by QIAGEN in 2010, and its diagnostic assays continue to be a cornerstone of QIAGEN's oncology portfolio for personalized medicine and clinical research.